Dr. Robert Waide Weaver, MD

Dr. Weaver practices at Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Tampa, Florida.

Dr. Weaver's NPI, 1578543799, was assigned on January 23, 2006. Dr. Weaver graduated from USF Health Morsani College of Medicine in 2000. Dr. Weaver holds Florida license ME87855.

Dr. Weaver's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West, at 3402 W Martin Luther King Jr Blvd, Tampa, FL 33607 in Hillsborough County. The practice phone is (239) 541-4633.

Dr. Weaver's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Tampa, Florida. Dr. Weaver is also affiliated with BayCare St. Joseph's Hospital. The medical group on file is Florida Cancer Specialists & Research Institute. Dmand AI also links Dr. Weaver to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Weaver practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Weaver's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Weaver is board certified in medical oncology by the American Board of Internal Medicine. Dr. Weaver is licensed in Florida.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), fluid and electrolyte imbalances and lung cancer among the conditions Dr. Weaver treats.

CMS data shows 46,925 Medicare services from Dr. Weaver across 41 procedure codes in 2024, for 757 Medicare patients. Medicare paid $372,764 for them. Every service was in an office.

CMS counts 757 Medicare patients who saw Dr. Weaver in 2024. The largest group is 75 to 84, with 306 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 2.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Weaver's median patient age at 65, with 70% women.

In 2024, Dr. Weaver wrote 1,037 Medicare Part D claims for 240 patients. 76% of them were for generic drugs. CMS names the drug for 807 of them, across 24 drugs with 11 or more claims each, at $1,409,742 in total drug cost. In 2023, CMS named 812 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Weaver for performance year 2024, reported as part of a group. Dr. Weaver accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Weaver as offering telehealth.

Dmand AI links 4 papers to Dr. Weaver, published from 2016 to 2021. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Carboplatin and Lung Neoplasms. Dr. Weaver's most frequent co-authors are David R. Spigel, MD, Michael J. McCleod, DO and Aditya Bardia, MD.

Dmand AI links Dr. Weaver to 3 clinical trials, 2 of them phase 2 studies. Conditions studied include Breast Neoplasms, Breast Diseases and Neoplasm Metastasis. Novartis Pharmaceuticals sponsors the most, 2.

CMS Open Payments shows 1,653 general payments to Dr. Weaver from 90 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 63% of the total. Eisai Inc. paid the most, $39,932. It also lists 2 research payments totaling $46,309 from 2016 to 2017.

Dmand AI lists 1 award for Dr. Weaver, most recently CMS Stage 1 EHR in 2014.

Dr. Weaver graduated from USF Health Morsani College of Medicine in 2000.

Dr. Weaver is in network with 19 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.